Effect of BIA 5 1058 on Cardiac Repolarization

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

October 5, 2018

Study Completion Date

October 5, 2018

Conditions
Cardiovascular DiseasePulmonary Arterial HypertensionHeart Failure
Interventions
DRUG

BIA 5-1058

"Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets"

DRUG

Placebo Oral Tablet

"Matching placebo tablets administered as follows:~\- placebo, as 12 × 0-mg tablets"

DRUG

Moxifloxacin 400 mg

"Administered as follows:~\- 400 mg moxifloxacin, as 1 × 400-mg tablet"

Trial Locations (1)

LS29LH

Covance Clinical Research Unit Ltd., Leeds

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Bial - Portela C S.A.

INDUSTRY